NEWS

Published Large U.S. Study Finds Comparable Effectiveness Between Adjuvanted and High-Dose Influenza Vaccines in Adults 65 Years and Older

• Large cluster-randomized crossover study involving nearly 430,000 U.S. adults aged 65 years and older was published in the Journal of the American Medical Association (JAMA) Network Open
• Adjuvanted and high-dose influenza vaccines did not differ in effectiveness against laboratory-confirmed influenza in any setting or influenza with emergency department visits or hospitalization
• Findings support existing NACI preferential recommendation for use of adjuvanted, higher dose or recombinant influenza vaccines in older adults

Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract

• CSL Seqirus will supply millions of doses of adjuvanted cell-based vaccine to support Canadians, in the event the World Health Organization (WHO) declares an influenza pandemic.
• The continued detection of influenza viruses of pandemic potential, including highly pathogenic avian influenza infecting wild birds, poultry and mammals, underscores the pandemic threat posed by influenza and the potential public health risk. [1]

Manufacturing facility opens in Australia

CSL Seqirus has recently opened its new high-tech cell-based influenza vaccine and antivenom manufacturing facility in Melbourne, Australia.

CSL Seqirus Presents Data at IDWeek 2025

Recent RWE data show cell-based influenza vaccines offer 20% greater protection in the prevention of test-confirmed influenza in pediatric and adult populations relative to standard egg-based influenza vaccines

Protection for Older Adults

CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable real-world evidence (RWE) reinforcing the critical role of enhanced influenza vaccines in preventing influenza and reducing the risks of severe disease at the 10th European Scientific Working group on Influenza (ESWI) conference in Valencia.